Literature DB >> 8081500

Hybrid anthracycline antibiotics: production of new anthracyclines by cloned genes from Streptomyces purpurascens in Streptomyces galilaeus.

J Niemi1, K Ylihonko, J Hakala, R Pärssinen, A Kopio, P Mäntsälä.   

Abstract

A DNA segment cloned from Streptomyces purpurascens ATCC 25489 close to a region that hybridized to a probe containing part of the actinorhodin polyketide synthase caused S. galilaeus ATCC 31615 to produce new anthracyclines. When transformed with certain sub-clones of this segment, the host produced glycosides of epsilon-rhodomycinone, beta-rhodomycinone, 10-demethoxycarbonylaklavinone and 11-deoxy-beta-rhodomycinone in addition to those of aklavinone, the natural anthracyclines of S. galilaeus. The first two compounds are S. purpurascens products and the other two are novel compounds that conceptually are structural hybrids between S. galilaeus and S. purpurascens products. Three glycosides of one of the novel aglycones, 11-deoxy-beta-rhodomycinone, were purified and found to possess cytotoxic activity against L1210 mouse leukaemia cells. Separate regions of the cloned S. purpurascens DNA are responsible for modification of the S. galilaeus host product at the 10- and 11-positions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081500     DOI: 10.1099/00221287-140-6-1351

Source DB:  PubMed          Journal:  Microbiology        ISSN: 1350-0872            Impact factor:   2.777


  10 in total

Review 1.  A comprehensive review of glycosylated bacterial natural products.

Authors:  Sherif I Elshahawi; Khaled A Shaaban; Madan K Kharel; Jon S Thorson
Journal:  Chem Soc Rev       Date:  2015-11-07       Impact factor: 54.564

2.  Nucleotide sequences and expression of genes from Streptomyces purpurascens that cause the production of new anthracyclines in Streptomyces galilaeus.

Authors:  J Niemi; P Mäntsälä
Journal:  J Bacteriol       Date:  1995-05       Impact factor: 3.490

3.  In vivo and in vitro bioconversion of epsilon-rhodomycinone glycoside to doxorubicin: functions of DauP, DauK, and DoxA.

Authors:  M L Dickens; N D Priestley; W R Strohl
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

4.  A gene cluster involved in nogalamycin biosynthesis from Streptomyces nogalater: sequence analysis and complementation of early-block mutations in the anthracycline pathway.

Authors:  K Ylihonko; J Tuikkanen; S Jussila; L Cong; P Mäntsälä
Journal:  Mol Gen Genet       Date:  1996-05-23

5.  Structure of the polyketide cyclase SnoaL reveals a novel mechanism for enzymatic aldol condensation.

Authors:  Azmiri Sultana; Pauli Kallio; Anna Jansson; Ji-Shu Wang; Jarmo Niemi; Pekka Mäntsälä; Gunter Schneider
Journal:  EMBO J       Date:  2004-04-08       Impact factor: 11.598

6.  Divergent evolution of an atypical S-adenosyl-l-methionine-dependent monooxygenase involved in anthracycline biosynthesis.

Authors:  Thadée Grocholski; Pedro Dinis; Laila Niiranen; Jarmo Niemi; Mikko Metsä-Ketelä
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

7.  Aclacinomycin oxidoreductase (AknOx) from the biosynthetic pathway of the antibiotic aclacinomycin is an unusual flavoenzyme with a dual active site.

Authors:  Igor Alexeev; Azmiri Sultana; Pekka Mäntsälä; Jarmo Niemi; Gunter Schneider
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-29       Impact factor: 11.205

8.  Analysis of clustered genes encoding both early and late steps in daunomycin biosynthesis by Streptomyces sp. strain C5.

Authors:  M L Dickens; J Ye; W R Strohl
Journal:  J Bacteriol       Date:  1995-02       Impact factor: 3.490

9.  Expression of Streptomyces peucetius genes for doxorubicin resistance and aklavinone 11-hydroxylase in Streptomyces galilaeus ATCC 31133 and production of a hybrid aclacinomycin.

Authors:  C K Hwang; H S Kim; Y S Hong; Y H Kim; S K Hong; S J Kim; J J Lee
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

Review 10.  Hybrid antibiotics.

Authors:  V Bĕhal
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.